© 1995 American Heart Association, Inc.
Articles |
Effect of Adenosine on Myocardial `Stunning' in the Dog
From the Experimental Research Laboratory, Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Tex.
Correspondence to Roberto Bolli, MD, Section of Cardiology, Baylor College of Medicine, 6535 Fannin, MS F-905, Houston, TX 77030.
Abstract Recent evidence suggests a cardioprotective effect of adenosine in myocardial ischemia and reperfusion. The present study was undertaken to determine (1) whether adenosine attenuates myocardial stunning, (2) if so, whether the beneficial effect of adenosine takes place during ischemia or after reperfusion, and (3) whether adenosine preconditions against myocardial stunning. A total of 93 dogs were used. In phase A of the study, open-chest dogs undergoing a 15-minute occlusion of the left anterior descending coronary artery followed by 4 hours of reperfusion received an intracoronary infusion of either saline (group I [control], n=14), 2 mg/min adenosine from 30 minutes before occlusion until 1 hour after reperfusion (group II, n=10), or 2 mg/min adenosine from 2 minutes before reperfusion until 1 hour after reperfusion (group III, n=11). Regional myocardial function (assessed as systolic wall thickening) was similar in the three groups at baseline and during ischemia. After reperfusion, dogs treated with adenosine before, during, and after ischemia (group II) demonstrated a significant improvement in the recovery of function that persisted throughout the 4 hours of reperfusion. In contrast, in dogs treated only during the reperfusion period (group III), the recovery of function was not statistically different from that in control dogs. The enhanced recovery effected by adenosine in group II could not be ascribed to differences in ischemic zone size, collateral flow during occlusion, coronary flow after reperfusion, arterial pressure, heart rate, or other hemodynamic variables. In phase B of the study, dogs received an intracoronary infusion of either saline (group IV [control], n=6) or adenosine (4 mg/min from 40 to 10 minutes before occlusion [group V, n=6]). Despite pretreatment with adenosine, the recovery of function in group V was indistinguishable from that in the control group. This study demonstrates that (1) continuous administration of adenosine before, during, and after ischemia results in a significant and sustained attenuation of myocardial stunning; (2) this improved recovery of function cannot be attributed to nonspecific variables, such as collateral flow during coronary occlusion, coronary flow after reperfusion, or other hemodynamic factors, and therefore reflects a direct cardioprotective action of adenosine; (3) the protection against stunning is lost or markedly diminished if adenosine is given only at reperfusion; and (4) administration of adenosine before ischemia does not precondition the myocardium against the stunning induced by a 15-minute occlusion. The failure of adenosine to produce a beneficial effect when given only at reperfusion indicates that in the 15-minute occlusion model, the nucleoside acts primarily by decreasing the severity of ischemic injury rather than by mitigating reperfusion injury.
Key Words: postischemic myocardial dysfunction • coronary reperfusion • preconditioning • adenosine
This article has been cited by other articles:
 |
|
 |
|
  R. M. Mentzer Jr, M. S. Jahania, and R. D. Lasley Myocardial Protection Card. Surg. Adult, January 1, 2008; 3(2008): 443 - 464. [Full Text]
|
|
|
|
 |
|
 D. K. Glover, M. Ruiz, K. Takehana, F. D. Petruzella, J. M. Rieger, T. L. Macdonald, D. D. Watson, J. Linden, and G. A. Beller Cardioprotection by adenosine A2A agonists in a canine model of myocardial stunning produced by multiple episodes of transient ischemia Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H3164 - H3171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Tune, M. W. Gorman, and E. O. Feigl Matching coronary blood flow to myocardial oxygen consumption J Appl Physiol, July 1, 2004; 97(1): 404 - 415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Headrick, B. Hack, and K. J. Ashton Acute adenosinergic cardioprotection in ischemic-reperfused hearts Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H1797 - H1818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. YELLON and J. M. DOWNEY Preconditioning the Myocardium: From Cellular Physiology to Clinical Cardiology Physiol Rev, October 1, 2003; 83(4): 1113 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Mentzer Jr., M. S. Jahania, and R. D. Lasley Myocardial Protection Card. Surg. Adult, January 1, 2003; 2(2003): 413 - 438. [Full Text]
|
|
|
|
|
|
R. D. Lasley, M. S. Jahania, and R. M. Mentzer Jr. Beneficial effects of adenosine A2a agonist CGS-21680 in infarcted and stunned porcine myocardium Am J Physiol Heart Circ Physiol, April 1, 2001; 280(4): H1660 - H1666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. W. Mahaffey, J. A. Puma, N. A. Barbagelata, M. F. DiCarli, M. A. Leesar, K. F. Browne, P. R. Eisenberg, R. Bolli, A. C. Casas, V. Molina-Viamonte, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) Trial J. Am. Coll. Cardiol., November 15, 1999; 34(6): 1711 - 1720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Ostadal, I. Ostadalova, and N. S. Dhalla Development of Cardiac Sensitivity to Oxygen Deficiency: Comparative and Ontogenetic Aspects Physiol Rev, July 1, 1999; 79(3): 635 - 659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bolli and E. Marban Molecular and Cellular Mechanisms of Myocardial Stunning Physiol Rev, April 1, 1999; 79(2): 609 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Auchampach and R. Bolli Adenosine receptor subtypes in the heart: therapeutic opportunities and challenges Am J Physiol Heart Circ Physiol, March 1, 1999; 276(3): H1113 - H1116. [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Lasley and R. M. Mentzer Jr. Dose-Dependent Effects of Adenosine on Interstitial Fluid Adenosine and Postischemic Function in the Isolated Rat Heart J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 806 - 811. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. A. Kloner, R. Bolli, E. Marban, L. Reinlib, and E. Braunwald Medical and Cellular Implications of Stunning, Hibernation, and Preconditioning : An NHLBI Workshop Circulation, May 19, 1998; 97(18): 1848 - 1867. [Full Text] [PDF]
|
|
|
|
|
|
H. T. Sommerschild, F. Grund, J. Offstad, P. Jynge, A. Ilebekk, and K. A. Kirkeboen Importance of Endogenous Adenosine During Ischemia and Reperfusion in Neonatal Porcine Hearts Circulation, November 4, 1997; 96(9): 3094 - 3103. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. A. Auchampach, A. Rizvi, Y. Qiu, X.-L. Tang, C. Maldonado, S. Teschner, and R. Bolli Selective Activation of A3 Adenosine Receptors With N6-(3-Iodobenzyl)Adenosine-5'-N-Methyluronamide Protects Against Myocardial Stunning and Infarction Without Hemodynamic Changes in Conscious Rabbits Circ. Res., June 19, 1997; 80(6): 800 - 809. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. D. Lasley and R. M. Mentzer Jr Cardioprotection by adenosine: Is it a question of effective dose, timing, or the target compartment? J. Thorac. Cardiovasc. Surg., July 1, 1996; 112(1): 203 - 204. [Full Text]
|
|
|
|
 |
|
 R. D. Lasley, M. A. Noble, P. J. Konyn, and R. M. Mentzer Jr Different Effects of an Adenosine A1 Analogue and Ischemic Preconditioning in Isolated Rabbit Hearts Ann. Thorac. Surg., December 1, 1995; 60(6): 1698 - 1703. [Abstract] [Full Text]
|
|